Alliance Pharmaceutical's Imavist
This article was originally published in The Gray Sheet
Ultrasound contrast agent FDA "approvable" letter completes review of the firm's new drug application, the firm announces Aug. 21. The NDA incorporated data from two Phase III multi-center studies on endocardial border delineation in about 500 U.S. patients and was submitted in October 1999. The product was developed jointly by Alliance and The German firm Schering AG. Alliance says it will "work closely with FDA to satisfy the remaining requirements" before final approval of the drug, which will be marketed by Schering
You may also be interested in...
3D-printing company Carbon and in vitro diagnostics maker Resolution Medical announced plans to manufacture more than one million 3D-printed nasal swabs per week to test for COVID-19. See what Resolution Medical’s president Shawn Patterson said about it here.
FDA warning to "Genesis II Church of Health and Healing " wasn't its first to the organization about promoting a chlorine dioxide formulation, "Miracle Mineral Solution," as an unapproved new drug. 'Infowars' host Alex Jones also was warned about bogus COVID-19 claims.
The first major revision since 2007 notably provides a legal foundation for special approvals under a public health crisis.